Macular Damage in Early Glaucoma and Progression
Completed
Conditions studied: Glaucoma
In brief
Glaucoma is the leading cause of irreversible blindness worldwide. This study aims to test a new method that may allow earlier diagnosis of glaucoma and better ways to monitor if it is getting worse. There is scientific evidence that the macula, the central part of the retina, can be involved in very early stages of glaucoma. Glaucomatous damage to the macula is very prevalent and is often missed using conventional clinical tests. Relatively little is known about progression of early glaucoma damage and its effects on the macula. This project investigates the nature of progressive damage to the macula and proposes new methods to improve accuracy to detect clinically significant progression.The study will evaluate the nature of damage to the macula's structures through OCT imaging and eye function via visual field tests.
Key facts
- Study ID
- NCT02547740
- Run by
- Columbia University
- People needed
- 260
- Starts
- 2015-10-01
- Expected to finish
- 2024-01-18
- Last updated by the study team
- 2024-05-14
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- glaucomatous optic neuropathy (as defined in the American Academy of Ophthalmology Preferred Practice Pattern criteria)
You may not qualify if…
- late functional glaucomatous damage
- significant cataract
- previous ocular surgery (aside from uncomplicated cataract extraction with intraocular lens (IOL) implantation and/or trabeculectomy, LASIK or refractive surgeries)
- diabetic retinopathy with macular edema
- vein or artery occlusion
- exudative age-related macular degeneration or geographic atrophy
- macular hole or traction
- amblyopia
- uveitis
- non-open angle glaucoma (e.g. angle closure, traumatic, congenital glaucoma)
- severe myopia or hyperopia (refractive error greater than -6 or +6D, respectively)
- retinal detachment (current or post-surgery)
- retinitis pigmentosa
- significant epiretinal memberane
- significant kerotoconus
- Healthy Group:
- Inclusion Criteria:
- best corrected visual acuity equal or better than 20/40
- normal biomicroscopy examination
- gonioscopically open angles
- Intraocular Pressure (IOP) lower than 22 mmHg
- normal and reliable 24-2 and 10-2 SAP results
- Exclusion Criteria:
- evidence of optic neuropathy
- evidence of clinically significant metabolic diseases (e.g. diabetes and hypotension)
Where it is running
- CUIMC Harkness Eye Institute — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.